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A bs tr ac t
Background
We have previously demonstrated an association between combination antiretroviral 
therapy and the risk of myocardial infarction. It is not clear whether this associa-
tion differs according to the class of antiretroviral drugs. We conducted a study to 
investigate the association of cumulative exposure to protease inhibitors and non-
nucleoside reverse-transcriptase inhibitors with the risk of myocardial infarction.
Methods
We analyzed data collected through February 2005 from our prospective observa-
tional study of 23,437 patients infected with the human immunodeficiency virus. 
The incidence rates of myocardial infarction during the follow-up period were calcu-
lated, and the associations between myocardial infarction and exposure to protease 
inhibitors or nonnucleoside reverse-transcriptase inhibitors were determined.
Results
Three hundred forty-five patients had a myocardial infarction during 94,469 person-
years of observation. The incidence of myocardial infarction increased from 1.53 per 
1000 person-years in those not exposed to protease inhibitors to 6.01 per 1000 
person-years in those exposed to protease inhibitors for more than 6 years. After 
adjustment for exposure to the other drug class and established cardiovascular risk 
factors (excluding lipid levels), the relative rate of myocardial infarction per year of 
protease-inhibitor exposure was 1.16 (95% confidence interval [CI], 1.10 to 1.23), 
whereas the relative rate per year of exposure to nonnucleoside reverse-transcriptase 
inhibitors was 1.05 (95% CI, 0.98 to 1.13). Adjustment for serum lipid levels further 
reduced the effect of exposure to each drug class to 1.10 (95% CI, 1.04 to 1.18) and 
1.00 (95% CI, 0.93 to 1.09), respectively.
Conclusions
Increased exposure to protease inhibitors is associated with an increased risk of 
myocardial infarction, which is partly explained by dyslipidemia. We found no 
evidence of such an association for nonnucleoside reverse-transcriptase inhibitors; 
however, the number of person-years of observation for exposure to this class of 
drug was less than that for exposure to protease inhibitors.
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Combination antiretroviral ther-apy has had a dramatic effect in reducing morbidity and mortality associated with 
human immunodeficiency virus type 1 (HIV-1) in-
fection.1-4 However, concern has been raised re-
garding the effect of such therapy on the risk of 
coronary heart disease. Previous findings from 
the Data Collection on Adverse Events of Anti-HIV 
Drugs (DAD) study indicated that the incidence 
of myocardial infarction increased with longer 
exposure to combination antiretroviral therapy.5
A central question is whether this observed 
risk is attributable to all antiretroviral drugs or 
only to specific drugs. Although previous studies 
have reported a relationship between protease-
inhibitor use and cardiovascular disease,6-8 there 
are few data on the risk associated with non-
nucleoside reverse-transcriptase inhibitors. Assess-
ment of the role of specific drug classes is com-
plicated by the fact that patients often switch 
components of their treatment because of the 
availability of newer drugs, the occurrence of ad-
verse events, or failure of their regimens.9-11
There have been 3 years of follow-up of pa-
tients in the DAD study since the initial report.5 
The additional data have made it possible to in-
vestigate the independent relationships between 
the risk of myocardial infarction and exposure to 




DAD is an international collaboration of 11 co-
horts of investigators following 23,437 HIV-1–
infected subjects at 188 clinics in 21 countries in 
Europe, the United States, and Australia. Details 
of the methods have been reported previously.5,12 
Patients were followed prospectively during their 
regular visits to outpatient clinics. All participants 
were under active follow-up in their cohorts at the 
time of enrollment in the study (from December 
1999 through April 2001). Data on sociodemo-
graphic features, clinical findings, treatment (anti-
retroviral and other medications received both 
before and after enrollment), and laboratory re-
sults were collected at enrollment and at least 
every 8 months thereafter with the use of stan-
dardized forms. All information was transformed 
into a standardized format and merged into a cen-
tral data set annually. Institutional review board 
approval for the study and written informed con-
sent from the study participants were obtained 
for each cohort individually, according to national 
and local regulations.
Outcomes
All incident cases of myocardial infarction were 
reported to the study coordinating office for val-
idation and coding.5 Cases of myocardial infarc-
tion were categorized as definite, possible, or un-
classifiable (e.g., sudden death in persons with 
no known terminal condition) and as fatal or non-
fatal according to criteria applied in the World 
Health Organization Multinational Monitoring of 
Trends and Determinants in Cardiovascular Dis-
ease (MONICA) Study.13,14 Event validation and 
coding were performed without knowledge of the 
antiretroviral-treatment history of a patient.
Statistical analysis
The DAD Steering Committee specified in 1999 
that analyses assessing the risk of myocardial 
infarction according to antiretroviral-drug class 
would be performed once sufficient events had 
accumulated to permit such analyses. Details of 
the analytic approach have been described previ-
ously.5 Patients were followed prospectively from 
enrollment in DAD to the date of the first myo-
cardial infarction, the date of death, 6 months 
after the patient’s last clinic visit, or February 1, 
2005, whichever occurred first. Each patient’s 
follow-up period was divided into consecutive 
1-month periods, and the patient’s cumulative ex-
posure to therapy at the start of each period was 
calculated (including exposure to treatment before 
enrollment). This information was used to assign 
the patient-month (and any events that occurred 
during that month) to the appropriate exposure 
category. All analyses were based on the first myo-
cardial infarction that occurred during follow-up. 
All P values are two-sided, and no adjustment was 
made for multiple testing.
Poisson regression models (GENMOD proce-
dure, SAS software, version 8) were used to quan-
tify the relationship between exposure to each 
drug class and the incidence of myocardial infarc-
tion. First, we reassessed the association with any 
combination antiretroviral therapy (i.e., a regimen 
of more than one antiretroviral drug, including at 
least one protease inhibitor, at least one nonnu-
cleoside reverse-transcriptase inhibitor, or both). 
The cumulative exposure to combination anti-
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retroviral therapy was categorized as no exposure, 
less than 1 year, 1 to 2 years, 2 to 3 years, 3 to 
4 years, 4 to 5 years, 5 to 6 years, 6 to 7 years, and 
more than 7 years and was incorporated as a 
continuous variable in subsequent analyses.
We then considered the unadjusted relationship 
between the incidence of myocardial infarction 
and cumulative exposure to protease inhibitors 
and nonnucleoside reverse-transcriptase inhibi-
tors. The primary Poisson regression models were 
then adjusted for demographic factors, calendar 
year, and conventional risk factors for cardiovas-
cular disease. Specific categories were generated 
for missing data (e.g., unknown family history) to 
ensure that all patients and observed events were 
included. In addition, in sensitivity analyses, we 
considered the relationships with cumulative ex-
posure to either drug class after exclusion of pa-
tients exposed to the other drug class.
In additional analyses, we assessed the role of 
established risk factors for myocardial infarction 
that may potentially be influenced by antiretro-
viral therapy, including diabetes or hypertension 
and the time-updated levels of serum lipids (total 
cholesterol, high-density lipoprotein [HDL] cho-
lesterol, and triglycerides [log2-transformed]). 
Lipid measurements were included regardless of 
fasting status. We also assessed the influence of 
markers of HIV-1 infection (CD4+ lymphocyte 
count nadir and peak HIV-1 RNA level).
R esult s
Patient characteristics and follow-up
The DAD study cohort included 23,437 patients 
(Table 1). The median age at enrollment was 39 
years (interquartile range, 34 to 45), and 24.1% of 
the patients were female. Among the 61.0% of pa-
tients for whom information on race or ethnic 
background (ascertained by different methods in 
different centers) was available, 77.9% were white, 
16.9% were black, 3.3% were Hispanic, 1.9% were 
Asian, and 0.1% (nine patients) were classified as 
“other.” The median nadir CD4+ lymphocyte 
count before enrollment was 200 cells per cubic 
millimeter (range, 1 to 2580), and 26.4% of pa-
tients had received a clinical diagnosis of the 
acquired immunodeficiency syndrome (AIDS). At 
enrollment, 60.8% of participants were current 
or former smokers, 3.1% had diabetes, 14.4% had 
hypertension, and 42.0% had dyslipidemia.
The total follow-up in this analysis was 94,469 
person-years, with a median of 4.5 years per pa-
tient. By the end of follow-up, 1518 patients (6.5%) 
had died. The average annual rate of loss to follow-
up, excluding deaths, was less than 3%.
Exposure to antiretroviral therapy
By the end of follow-up, 93.6% of the patients 
had been exposed to some form of antiretroviral 
therapy, totaling 150,775 person-years of expo-
sure, with a median exposure of 6.9 years (Table 1). 
Of all the patients, 79.4% had been exposed to 
protease inhibitors for a median of 4.0 years, and 
63.7% had been exposed to nonnucleoside reverse-
transcriptase inhibitors for a median of 2.6 years. 
There was a total of 72,846 person-years of ex-
posure to protease inhibitors (including 41,297 
person-years of exposure to ritonavir-containing 
regimens) and 52,457 person-years of exposure to 
nonnucleoside reverse-transcriptase inhibitors.
Myocardial infarction
Three hundred forty-five patients had a fatal or 
nonfatal myocardial infarction (incidence, 3.65 per 
1000 person-years) (Table 1). Of these, 62.6% were 
definite, 22.6% were possible, and 14.8% were 
unclassifiable; 29.3% were fatal. By the time of 
the event, 90.4% of patients who had a myocardial 
infarction had been exposed to protease inhibi-
tors (median exposure, 3.7 years), and 60.9% had 
been exposed to nonnucleoside reverse-transcrip-
tase inhibitors (median exposure, 2.1 years).
association of Antiretroviral Therapy  
with the Risk of Myocardial Infarction
We confirmed our previous observation that in-
creased exposure to combination antiretroviral 
therapy was associated with an increased risk of 
myocardial infarction (adjusted relative rate, 1.16 
per year of exposure; 95% confidence interval [CI], 
1.09 to 1.23) (Fig. 1). The therapy-attributed rela-
tive rate did not differ significantly between men 
(relative rate, 1.13) and women (relative rate, 1.36; 
P value for interaction = 0.40) or between older 
patients (≥45 years of age for men, and ≥55 years 
of age for women; relative rate, 1.15) and younger 
patients (relative rate, 1.16; P value for interac-
tion = 0.19).
The incidence of myocardial infarction in-
creased with increasing length of exposure to ei-
ther class of drugs (Fig. 2A and Table 2, unadjust-
ed model); for example, the incidence increased 
from 1.53 per 1000 person-years among those not 
The New England Journal of Medicine 
Downloaded from nejm.org at COLUMBIA UNIV HEALTH SCIENCES LIB on October 16, 2015. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 356;17 www.nejm.org april 26, 20071726
Table 1. Characteristics of the Patients at Baseline and at Last Follow-up.*
Characteristic Baseline Last Follow-up
All Patients
(N = 23,437)













Female sex — no. (%) 5649 (24.1) 31 (9.0) Unchanged Unchanged
Age — yr 
Median 39 46 43 49
Interquartile range 34–45 39–54 38–49 42–57
Race or ethnic group — no./total no. (%)† Unchanged Unchanged
White 11,130/14,291 (77.9) 210/234 (89.7)
Black 2,413/14,291 (16.9) 21/234 (9.0)
Hispanic 466/14,291 (3.3) 2/234 (0.9)
Asian 273/14,291 (1.9) 1/234 (0.4)
Other 9/14,291 (0.1) 0/234
Body-mass index‡
>30 — no./total no. (%) 934/19,857 (4.7) 20/293 (6.8) 1,114/21,342 (5.2) 21/305 (6.8)
Median 23.0 23.1 22.9 23.1
Interquartile range 21.0–25.2 21.3–25.6 20.9–25.3 20.8–25.7
Cardiovascular risk factors
Current or former smoker — no./total no. (%) 10,893/17,911 (60.8) 196/264 (74.2) 14,053/19,558 (71.9) 225/279 (80.6)
Family history of coronary heart disease — no./total no. (%)§ 1,415/17,035 (8.3)  32/237 (13.5)  1,899/17,440 (10.9)  38/229 (16.6)
Previous cardiovascular disease — no. (%)¶ 387 (1.7) 56 (16.2) 910 (3.9)  64 (18.6)
Hypertension — no. (%)‖ 3,381 (14.4) 101 (29.3) 5,575 (23.8) 131 (38.0)
Systolic blood pressure — mm Hg
Median 120 126 120 130
Interquartile range 110–130 120–140 113–130 120–140
Diastolic blood pressure — mm Hg
Median 80 80 80 80
Interquartile range 70–80 72–85 70–83 70–85
Diabetes mellitus — no. (%)** 735 (3.1) 49 (14.2) 1,271 (5.4)  57 (16.5)
Dyslipidemia — no. (%)†† 9,833 (42.0) 224 (64.9) 11,389 (48.6) 238 (69.0)
Serum total cholesterol — mmol/liter‡‡ 
Median 5.0 5.9 5.0 5.8
Interquartile range 4.2–6.0 5.0–7.0 4.2–5.8 4.9–6.7
Serum HDL cholesterol — mmol/liter‡‡
Median 1.1 1.0 1.1 1.1
Interquartile range 0.9–1.4 0.8–1.2 0.9–1.4 0.9–1.3
Serum triglycerides — mmol/liter§§
Median 1.7 2.5 1.7 2.4
Interquartile range 1.1–2.8 1.6–3.9 1.1–2.7 1.6–3.9
Ratio of total to HDL cholesterol
Median 4.4 5.6 4.3 5.7
Interquartile range 3.4–5.6 4.5–6.6 3.4–5.5 4.4–6.9
Use of lipid-lowering agents — no. (%) 944 (4.0) 46 (13.3) 2,367 (10.1) 79 (22.9)
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Table 1. (Continued.)
Characteristic Baseline Last Follow-up
All Patients
(N = 23,437)













Clinical diagnosis of AIDS — no. (%)  6,191 (26.4) 117 (33.9)  7,170 (30.6) 127 (36.8)
HIV-1 RNA — log10 copies/ml 
Median 2.6 2.4 1.7 1.9
Interquartile range 1.7–4.0 1.7–3.8 1.7–3.5 1.7–3.3
CD4+ lymphocyte count — cells/mm3
Median 420 368 461 411
Interquartile range 258–617 222–569 297–661 270–618
Hemoglobin — mmol/liter¶¶
Median 8.8 8.9 8.8 8.9
Interquartile range 8.1–9.4 8.2–9.5 8.0–9.4 8.1–9.4
Lipodystrophy (including lipoatrophy) — no. (%)  5,135 (21.9) 107 (31.0)  7,844 (33.5) 131 (38.0)
Antiretroviral therapy 
Not exposed to antiretroviral therapy — no. (%)  4,157 (17.7) 19 (5.5) 1,511 (6.4) 5 (1.4)
Exposed to antiretroviral therapy — no. (%) 19,267 (82.2) 326 (94.5) 21,926 (93.6) 340 (98.6)
Cumulative exposure for those exposed — yr
Median 3.4 4.2 6.9 6.1
Interquartile range 2.0–5.0 2.7–5.8 4.7–8.8 4.2–8.2
Exposed to protease inhibitors — no. (%) 16,096 (68.7) 292 (84.6) 18,607 (79.4) 312 (90.4)
Cumulative exposure for those exposed — yr
Median 2.4 2.7 4.0 3.7
Interquartile range 1.4–3.2 1.9–3.4 2.3–6.2 2.4–5.1
Exposed to nonnucleoside reverse-transcriptase 
 inhibitors — no. (%)
 8,163 (34.8) 149 (43.2) 14,932 (63.7) 210 (60.9)
Cumulative exposure for those exposed — yr
Median 0.9 1.1 2.6 2.1
Interquartile range 0.4–1.5 0.6–1.8 1.2–4.4 0.9–3.1
* Data for some characteristics were not available for all patients. HDL denotes high-density lipoprotein, AIDS the acquired immunodefi-
ciency syndrome, and HIV human immunodeficiency virus.
† Race was self-assessed or ascertained by health care personnel, depending on the clinic. The percentages for the entire cohort do not sum 
to 100 because of rounding.
‡ The body-mass index is the weight in kilograms divided by the square of the height in meters.
§ A family history of coronary heart disease was defined as at least one first-degree relative who had had the disease before the age of 50 years.
¶ Previous cardiovascular events were defined as a history of myocardial infarction, stroke, or invasive procedures for stenosis of the carotid 
or coronary arteries.
‖ Hypertension was defined as a systolic blood pressure of at least 140 mm Hg, a diastolic blood pressure of at least 90 mm Hg, or use of 
antihypertensive drugs.
** Patients with diabetes were defined as those who had a diagnosis of diabetes or were taking antidiabetic drugs. 
†† Dyslipidemia was defined as a total serum cholesterol level of at least 6.2 mmol per liter (240 mg per deciliter), a total triglyceride level  
of at least 2.3 mmol per liter (204 mg per deciliter), an HDL cholesterol level of 0.9 mmol per liter (35 mg per deciliter) or less, or use of 
lipid-lowering drugs.
‡‡ To convert values for cholesterol to milligrams per deciliter, divide by 0.02586.
§§ To convert values for triglycerides to milligrams per deciliter, divide by 0.01129.
¶¶ To convert values for hemoglobin to grams per deciliter, divide by 0.6206.
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exposed to protease inhibitors to 6.01 per 1000 
person-years among those exposed to protease 
inhibitors for more than 6 years. However, be-
cause many patients had been exposed to both 
drug classes, the unadjusted event rates are not 
independent. After adjustment for exposure to the 
other drug class, calendar year, and other known 
risk factors for myocardial infarction (excluding 
those that have been reported to have an associa-
tion with antiretroviral-drug therapy), the relative 
rate per year of exposure to protease inhibitors 
was 1.16 (95% CI, 1.10 to 1.23), whereas for non-
nucleoside reverse-transcriptase inhibitors it was 
1.05 (95% CI, 0.98 to 1.13; Fig. 2B and Table 2, 
adjusted model 1). These associations were con-
firmed when patients exposed to the other drug 
class were excluded (Fig. 3). The adjusted relative 
rate per year of exposure to protease inhibitors 
for this subgroup of patients was 1.15 (95% CI, 
1.06 to 1.25). The adjusted relative rate per year 
of exposure to nonnucleoside reverse-transcrip-
tase inhibitors was 0.94 (95% CI, 0.74 to 1.19).
The crude incidence rate of myocardial infarc-
tion was increased among patients who received 
drugs of both classes at the same time (97 events 
in 16,805 person-years; incidence, 5.77 per 1000 
person-years) as compared with the entire cohort 
(incidence, 3.65 per 1000 person-years). However, 
this difference was explained by the longer ex-
posure to protease inhibitors of patients receiving 
drugs of both classes (relative rate for exposure 
to both drug classes after adjustment for duration 
of exposure to each class, 1.03 per year).
Controlling for exposure to nucleoside reverse-
transcriptase inhibitors as a class reduced the 
strength of the associations for protease inhibi-
tors (relative rate, 1.11; 95% CI, 1.04 to 1.18) and 
for nonnucleoside reverse-transcriptase inhibitors 
(relative rate, 1.02; 95% CI, 0.95 to 1.10). There 
were no major differences between the two drug 
classes in exposure to individual components 
of the nucleoside reverse-transcriptase inhibitor 
backbone.
Increased total cholesterol and reduced HDL 
cholesterol levels, increased triglyceride levels, 
and a diagnosis of hypertension or diabetes are 
risk factors for coronary heart disease that have 













































































Figure 1. Risk of Myocardial Infarction According to Exposure to Combination Antiretroviral Therapy.
The crude incidence of primary events was assessed beginning at baseline according to the cumulative duration of 
combination antiretroviral therapy since the initiation of therapy, stratified in 1-year intervals from the initiation of 
therapy to more than 7 years of exposure. The adjusted re ative rate of myocardial infarction according to cumulative 
exposure to combination antiretroviral therapy was 1.16 per year of exposure (95% CI, 1.09 to 1.23). The estimate 
was based on a Poisson regression model. The multivariable model was adjusted for age, sex, family history of coro-
nary heart disease, body-mass index, smoking status, history of cardiovascular disease, cohort, transmission group, 
race or ethnic group, and calendar year. The sum of the person-years does not total 94,469 because of rounding. 
The I bars denote the 95% CIs.
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Figure 2. Risk of Myocardial Infarction According to Exposure to Protease Inhibitors and Nonnucleoside Reverse-
Transcriptase Inhibitors.
Cumulative exposure was categorized as no exposure, less than 1 year, 1 to 2 years, 2 to 3 years, 3 to 4 years, 4 to  
5 years, 5 to 6 years, and more than 6 years for protease inhibitors and as no exposure, less than 1 year, 1 to 2 years, 
2 to 3 years, 3 to 4 years, and more than 4 years for nonnucleoside reverse-transcriptase inhibitors. Panel A shows 
the incidence of primary events according to the cumulative exposure to protease inhibitors and nonnucleoside 
 reverse-transcriptase inhibitors. Panel B shows the adjusted relative rates of myocardial infarction according to the 
 cumulative exposure to protease inhibitors and nonnucleoside reverse-transcriptase inhibitors. The estimates were 
based on Poisson regression models. The multivariable model was adjusted for sex, cohort, HIV transmission group, 
race or ethnic group, age, body-mass index, family history of cardiovascular disease, smoking status, previous cardio-
vascular event, and calendar year. The sum of th  person-ye rs may not total 94,469 because of rounding. The I bars 
denote the 95% CIs.
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Table 2. Relationship between Exposure to Protease Inhibitors, Nonnucleoside Reverse-Transcriptase Inhibitors, and Other Cardiovascular 
Risk Factors and the Rate of Myocardial Infarction.*
Variable Unadjusted Model Adjusted Model 1† Adjusted Model 2‡
Relative Rate  
(95% CI) P Value
Relative Rate  
(95% CI) P Value
Relative Rate  
(95% CI) P Value
Exposure to protease inhibitors (per additional 
year)
1.17 (1.12–1.23) <0.001 1.16 (1.10–1.23) <0.001 1.10 (1.04–1.18) 0.002
Exposure to nonnucleoside reverse-transcriptase 
inhibitors (per additional year)
1.07 (1.00–1.14) 0.04 1.05 (0.98–1.13) 0.17 1.00 (0.93–1.09) 0.92
Age (per additional 5 yr) 1.41 (1.35–1.48) <0.001 1.39 (1.31–1.46) <0.001 1.32 (1.23–1.41) <0.001
Male sex 3.27 (2.26–4.73) <0.001 1.91 (1.28–2.86) 0.002 2.13 (1.29–3.52) 0.003
Body-mass index§
<18 0.74 (0.37–1.50) 0.41 0.74 (0.36–1.50) 0.40 0.92 (0.43–1.97) 0.84
18–26¶ 1 1 1
>26–30 1.12 (0.82–1.53) 0.47 1.06 (0.78–1.45) 0.70 0.88 (0.61–1.27) 0.48
>30 1.41 (0.90–2.20) 0.13 1.70 (1.08–2.69) 0.02 1.34 (0.77–2.34) 0.31
Not known 1.14 (0.81–1.59) 0.46 1.19 (0.84–1.71) 0.33 1.34 (0.86–2.09) 0.19
Family history of coronary heart disease‖
No¶ 1 1 1
Yes 1.83 (1.29–2.59) <0.001 1.56 (1.10–2.23) 0.01 1.40 (0.96–2.05) 0.08
Not known 1.48 (1.17–1.86) <0.001 1.64 (1.20–2.24) 0.002 1.32 (0.92–1.91) 0.13
Smoking status
Current 2.17 (1.59–2.94) <0.001 2.83 (2.04–3.93) <0.001 2.92 (2.04–4.18) <0.001
Former 1.96 (1.35–2.86) <0.001 1.65 (1.12–2.42) 0.01 1.63 (1.07–2.48) 0.02
Never¶ 1 1 1
Not known 1.83 (1.28–2.63) 0.001 1.70 (1.07–2.71) 0.03 1.67 (0.96–2.92) 0.07
Previous cardiovascular event
No¶ 1 1 1
Yes 9.72 (7.06–13.38) <0.001 4.30 (3.06–6.03) <0.001 4.64 (3.22–6.69) <0.001
Diabetes mellitus** 4.05 (3.05–5.38) <0.001 — — 1.86 (1.31–2.65) <0.001
Hypertension†† 2.53 (1.99–3.21) <0.001 — — 1.30 (0.99–1.72) 0.06
Total cholesterol (per mmol/liter increase) 1.31 (1.25–1.37) <0.001 — — 1.26 (1.19–1.35) <0.001
HDL cholesterol (per mmol/liter increase) 0.65 (0.48–0.88) <0.001 — — 0.72 (0.52–0.99) 0.05
Triglycerides (per doubling of the concentration)‡‡ 1.58 (1.43–1.75) <0.001 — — — —
* All 23,437 patients were included in the models shown. CI denotes confidence interval, dashes not applicable, and HDL high-density lipoprotein.
† The primary model (model 1) was adjusted for sex, cohort, HIV transmission group, race or ethnic group (all fixed at enrollment in DAD), 
age, body-mass index, family history of cardiovascular disease, smoking status, previous cardiovascular event, and calendar year (all time-
updated to allow a patient’s status to change over time).
‡ In an additional exploratory model (model 2), we assessed the role of established risk factors for myocardial infarction that may potentially 
be influenced by antiretroviral therapy, including the levels of serum lipids (total cholesterol and HDL cholesterol), hypertension, and the 
presence of diabetes mellitus. For each variable, the patient’s most recent measurement at the start of each month was incorporated into 
the model in a time-updated manner (this analysis excluded patients with missing information on covariates). Thus, the latter analysis al-
lowed us to assess potential mechanisms for any apparent relationship between myocardial infarction and exposure to therapy. The model 
was also adjusted for the same factors as model 1.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ The patients in this category served as the reference group.
‖ A family history of coronary heart disease was defined as at least one first-degree relative who had had the disease before the age of 50 years.
** Patients with diabetes were defined as those who had a diagnosis of diabetes or were taking antidiabetic drugs.
†† Hypertension was defined as a systolic blood pressure of at least 140 mm Hg, a diastolic blood pressure of at least 90 mm Hg, or use of 
antihypertensive drugs.
‡‡ Because of the strong associations among the three lipid measurements, triglycerides were not included in the multivariable model.
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Figure 3. Risk of Myocardial Infarction According to Exposure to Protease Inhibitors and Nonnucleoside Reverse-
Transcriptase Inhibitors among Patients Unexposed to the Other Drug Class.
Cumulative exposure was categorized as no exposure, less than 1 year, 1 to 2 years, 2 to 3 years, 3 to 4 years, 4 to  
5 years, 5 to 6 years, and more than 6 years for protease inhibitors and as no exposure, less than 1 year, 1 to 2 years, 
2 to 3 years, 3 to 4 years, and more than 4 years for nonnucleoside reverse-transcriptase inhibitors. Panel A shows 
the incidence of myocardial infarction according to the cumulative exposure to protease inhibitors and nonnucleoside 
reverse-transcriptase inhibitors among patients who had not been exposed to the other drug class. The crude inci-
dence rates among patients exposed to nonnucleoside analogues were considerably lower in this analysis than in 
the analysis including all subjects (Fig. 2A), although the confidence intervals were much wider because of the smaller 
number of subjects included in these analyses. Panel B shows the unadjusted relative rates of myocardial infarction 
according to exposure to protease inhibitors and no nucleoside rev rse-transcriptase inhibitors among patients who 
had not been exposed to the other drug class. After exposures were fitted as continuous variables, the adjusted rela-
tive rate per year of exposure to protease inhibitors was 1.15 (95% CI, 1.06 to 1.25), and per year of exposure to non-
nucleoside reverse-transcriptase inhibitors was 0.94 (95% CI, 0.74 to 1.19). These are two separate analyses, which 
were both adjusted for age, sex, family history of coronary heart disease, body-mass index, smoking status, history 
of cardiovascular disease, transmission group, race or ethnic group, and calendar year. The I bars denote the 95% CIs.
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drug therapy. We confirmed that in our cohort, 
these factors were all associated with an increased 
risk of myocardial infarction in unadjusted analy-
ses (Table 2, unadjusted model). Introducing 
these factors into adjusted model 1 in Table 2 as 
time-updated covariates decreased the association 
between exposure to protease inhibitors and the 
risk of myocardial infarction (Table 2, adjusted 
model 2). A model that included the lipids only 
(without diabetes mellitus and hypertension) re-
duced the association with protease inhibitors 
to a value similar to that in adjusted model 2.
There was no association between either the 
nadir CD4+ lymphocyte count (relative rate for 
each increase of 50 cells per cubic millimeter, 
0.98; 95% CI, 0.95 to 1.01) or peak HIV-1 RNA 
level (relative rate for each log10 increase in the 
number of copies per milliliter, 1.06; 95% CI, 
0.95 to 1.18) and the risk of myocardial infarc-
tion. Adjustment for these variables did not mod-
ify the association between exposure to protease 
inhibitors and the risk of myocardial infarction.
Discussion
Using a data set that has accrued almost three 
times more end points in the 3 years of follow-up 
since the last report,5 we continue to observe an 
association between exposure to combination anti-
retroviral therapy and the risk of myocardial in-
farction. The relationship between exposure to 
protease inhibitors and myocardial infarction re-
mained significant after multivariable adjustment 
and was similar to the relationship between expo-
sure to any combination antiretroviral therapy 
and the risk of myocardial infarction. In contrast, 
exposure to nonnucleoside reverse-transcriptase 
inhibitors was not independently associated with 
an increase in the risk of myocardial infarction. 
Although experience with nonnucleoside reverse-
transcriptase inhibitors remains relatively limited, 
our results suggest that the previously reported 
finding of an excess risk in those with increased 
exposure to combination antiretroviral therapy is 
likely to be a consequence of exposure to the 
drugs of the protease-inhibitor class.
Protease inhibitors are known to increase total 
cholesterol and low-density lipoprotein cholester-
ol levels to a greater extent than do nonnucleoside 
reverse-transcriptase inhibitors, whereas the latter 
class of agents is known to increase HDL choles-
terol levels markedly.15-17 However, the increased 
risk of myocardial infarction associated with the 
use of protease inhibitors seen in our analysis 
was not fully explained by the lipid changes in-
duced by the drugs in this class. Thus, the full 
mechanism by which protease inhibitors may lead 
to increased rates of myocardial infarction re-
mains to be elucidated. Recently published ex-
perimental data from murine models suggest 
possible direct cellular mechanisms by which 
HIV protease inhibitors may promote atheroscle-
rosis.18,19 Furthermore, there are considerable 
differences among the various protease inhibitors 
in their propensity to cause dyslipidemia.16,20 The 
DAD study currently has insufficient follow-up 
observations to determine whether the risk of myo-
cardial infarction differs for individual agents.
Some studies have reported that among pa-
tients receiving antiretroviral therapy, the degree 
of dyslipidemia or the risk of coronary heart dis-
ease is higher in women21,22 or in younger pa-
tients.23 In our analysis, we did not find any evi-
dence that the therapy-attributable risk differs 
according to age or sex.
In our study, the relative rate of myocardial 
infarction was 1.16 per year of combination anti-
retroviral therapy, which corresponds to a dou-
bling of the risk over a 5-year period of exposure. 
The magnitude of this association is similar to 
the increment in risk attributable to diabetes mel-
litus or cigarette smoking and is greater than 
that associated with a family history of cardio-
vascular disease. Whether this effect translates 
into an important additional absolute risk in a 
person depends on his or her preexisting cardio-
vascular-disease risk profile. In this regard, our 
analysis confirmed that the expected associations 
of established cardiovascular risk factors with 
myocardial infarction are also seen in the patient 
population of the DAD study, but our models 
were not intended to provide the formal basis for 
calculating individual cardiovascular risk.
We found no association between either the 
peak HIV-1 RNA level or the nadir CD4+ lym-
phocyte count and the risk of myocardial infarc-
tion, although the possibility that other unmea-
sured immunologic effects may exert an influence 
on the development of cardiovascular disease can-
not be excluded. The Strategies for Management 
of Antiretroviral Therapy (SMART) study found 
that the risk of opportunistic disease or death 
from any cause was higher in patients whose 
antiretroviral therapy was interrupted when their 
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CD4+ lymphocyte count reached a certain level 
than in patients who received continuous treat-
ment.24 Surprisingly, the interruption strategy was 
also associated with a trend toward an excess risk 
of cardiovascular disease. The reasons for this 
finding remain unclear. Theoretically, it could be 
due to arterial inflammation, a reduction in HDL 
cholesterol levels, or both caused by an acute-
onset increase in viral replication upon interrup-
tion of antiretroviral treatment.25-28 The latter 
effect may be particularly important after discon-
tinuation of nonnucleoside reverse-transcriptase 
inhibitors, since these may in themselves cause 
a rise in HDL cholesterol level.15-17
Only a randomized trial, which is not feasible 
in this setting, could determine whether the ob-
served associations of exposure to protease in-
hibitors and nonnucleoside reverse-transcriptase 
inhibitors with the risk of myocardial infarction 
are causally related. The DAD study, which is ob-
servational in design, relies on adjustment of the 
analyses of association for variables that could 
potentially act as confounders for these associa-
tions. In our analysis, we made adjustments for 
patient demographics and for the established car-
diovascular risk factors. We also adjusted for 
calendar year to account for secular changes in 
the management of cardiovascular disease and 
in the use of antiretroviral agents.
However, there are likely to be other confound-
ing factors that are unknown or are not routine-
ly or easily identified or measured. One possible 
interpretation of the significant relationship be-
tween the risk of myocardial infarction and the 
length of exposure to combination antiretroviral 
therapy may be simply that patients with longer 
periods of exposure to therapy have also been in-
fected with HIV for longer periods. However, our 
findings that neither the nadir CD4+ count nor 
the peak HIV-1 RNA level was associated with 
the risk of myocardial infarction would argue 
against this interpretation, as would the finding 
that the risk is different for exposure to nonnu-
cleoside reverse-transcriptase inhibitors and ex-
posure to protease inhibitors.
Another possible concern in observational stud-
ies of this type is channeling bias. In our study, 
channeling bias could have occurred if patients 
perceived to be at highest risk for cardiovascular 
disease were either started on or switched to regi-
mens thought to be cardioprotective. Such a bias 
would tend to reduce the strength of the associa-
tion of protease-inhibitor exposure with the risk 
of myocardial infarction. The fact that our analy-
ses are adjusted for most known risk factors for 
cardiovascular disease reduces the likelihood that 
channeling has unduly influenced our results. In 
addition, we assessed the relationship of myo-
cardial infarction with cumulative exposure to 
an antiretroviral drug rather than with current 
treatment with an antiretroviral drug, which fur-
ther reduces the chance of significant bias. Final-
ly, other analyses from the DAD study29 suggest 
that changes in therapy made because of con-
cern about cardiovascular disease are unlikely to 
have been frequent enough to bias our results.
In conclusion, this analysis confirmed our 
previous observation of a significant association 
between the duration of exposure to combination 
antiretroviral therapy and the risk of myocardial 
infarction. In addition, our findings suggest that 
this effect of antiretroviral therapy varies accord-
ing to drug class; we found a significant asso-
ciation between exposure to protease inhibitors 
and the risk of myocardial infarction but no 
significant association between nonnucleoside 
reverse-transcriptase inhibitors and such a risk. 
The effect of protease inhibitors identified in our 
study may be in part a consequence of the effects 
of these agents on serum lipid profiles.
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